Biomea Fusion Inc BMEA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials
-
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
-
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
Trading Information
- Previous Close Price
- $8.77
- Day Range
- $8.70–10.20
- 52-Week Range
- $3.61–22.74
- Bid/Ask
- $9.60 / $9.72
- Market Cap
- $346.53 Mil
- Volume/Avg
- 4.3 Mil / 692,927
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 112
- Website
- https://www.biomeafusion.com
Comparables
Valuation
|
Metric
|
BMEA
|
ERAS
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.05 | 1.66 | 0.63 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
BMEA
ERAS
PRLD
Financial Strength
|
Metric
|
BMEA
|
ERAS
|
PRLD
|
|---|---|---|---|
Quick Ratio | 0.00 | 16.41 | 7.71 |
Current Ratio | 4.62 | 16.79 | 7.83 |
Interest Coverage | — | — | — |
Quick Ratio
BMEA
ERAS
PRLD
Profitability
|
Metric
|
BMEA
|
ERAS
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −62.52% | −25.42% | −40.98% |
Return on Equity (Normalized) | −73.48% | −31.11% | −46.70% |
Return on Invested Capital (Normalized) | −74.59% | −31.15% | −44.57% |
Return on Assets
BMEA
ERAS
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mjsvczhz | Hysr | $566.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ynzrybhq | Fxsldg | $119.2 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cctdxbss | Zyslkfq | $113.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dwwqklncg | Wsyjtbm | $35.0 Bil | |||
| argenx SE ADR
ARGX
| Dgnxthnp | Dccdq | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Dlzwbthh | Bvf | $27.5 Bil | |||
| Moderna Inc
MRNA
| Jfszynrt | Wgmh | $24.5 Bil | |||
| United Therapeutics Corp
UTHR
| Xnsjvth | Lvy | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Crkmrtvh | Qhsnph | $13.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fmhhgttbsj | Mfrzpzz | $12.4 Bil |
United States